Table of Contents Author Guidelines Submit a Manuscript
Interdisciplinary Perspectives on Infectious Diseases
Volume 2009 (2009), Article ID 984934, 5 pages
http://dx.doi.org/10.1155/2009/984934
Research Article

In Vitro Synergy of Levofloxacin Plus Piperacillin/Tazobactam against Pseudomonas aeruginosa

1Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
2Premier Infectious Disease Care, 320 Edinburgh Dr., Winter Park, FL 32792, USA

Received 1 June 2009; Revised 30 August 2009; Accepted 9 September 2009

Academic Editor: Melinda Pettigrew

Copyright © 2009 Vladimir Chachanidze et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. P. Ouderkirk, J. A. Nord, G. S. Turett, and J. W. Kislak, “Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria,” Antimicrobial Agents and Chemotherapy, vol. 47, no. 8, pp. 2659–2662, 2003. View at Publisher · View at Google Scholar
  2. D. M. Livermore, “Of Pseudomonas, porins, pumps and carbapenems,” Journal of Antimicrobial Chemotherapy, vol. 47, no. 3, pp. 247–250, 2001. View at Google Scholar
  3. M. N. AI-Hasan, J. W. Wilson, B. D. Lahr et al., “β-lactam and fluoroquinolone combination antibiotic therapy for bacteremia caused by gram-negative bacilli,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 4, pp. 1386–1394, 2009. View at Publisher · View at Google Scholar · View at PubMed
  4. C. M. Flynn, D. M. Johnson, and R. N. Jones, “In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains,” Journal of Chemotherapy, vol. 8, no. 6, pp. 411–415, 1996. View at Google Scholar
  5. S. L. Pendland, C. R. Messick, and R. Jung, “In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa,” Diagnostic Microbiology and Infectious Disease, vol. 42, no. 1, pp. 75–78, 2002. View at Publisher · View at Google Scholar
  6. E. Fodor, E. Hajdú, and E. Nagy, “Use of Etest to assess synergy of antibiotic combinations against clinical isolates of Pseudomonas spp.,” International Journal of Antimicrobial Agents, vol. 25, no. 2, pp. 183–184, 2005. View at Publisher · View at Google Scholar · View at PubMed
  7. D. S. Burgess, R. G. Hall, and T. C. Hardin, “In vitro evaluation of the activity of two doses of levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa,” Diagnostic Microbiology and Infectious Disease, vol. 46, no. 2, pp. 131–137, 2003. View at Publisher · View at Google Scholar
  8. D. S. Burgess and S. Nathisuwan, “Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa,” Diagnostic Microbiology and Infectious Disease, vol. 44, no. 1, pp. 35–41, 2002. View at Publisher · View at Google Scholar
  9. L. Drago, E. De Vecchi, L. Nicola, A. Colombo, A. Guerra, and M. R. Gismondo, “Activity of levofloxacin and ciprofloxacin in combination with cefepime, ceftazidime, imipenem, piperacillin-tazobactam and amikacin against different Pseudomonas aeruginosa phenotypes and Acinetobacter spp.,” Chemotherapy, vol. 50, no. 4, pp. 202–210, 2004. View at Publisher · View at Google Scholar · View at PubMed
  10. R. L. White, D. S. Burgess, M. Manduru, and J. A. Bosso, “Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test,” Antimicrobial Agents and Chemotherapy, vol. 40, no. 8, pp. 1914–1918, 1996. View at Google Scholar
  11. C. R. Bonapace, R. L. White, L. V. Friedrich, and J. A. Bosso, “Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with E test, time-kill, and checkerboard methods,” Diagnostic Microbiology and Infectious Disease, vol. 38, no. 1, pp. 43–50, 2000. View at Publisher · View at Google Scholar
  12. A. S. Bayer and J. O. Morrison, “Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus,” Antimicrobial Agents and Chemotherapy, vol. 26, no. 2, pp. 220–223, 1984. View at Google Scholar
  13. D. M. Cappelletty and M. J. Rybak, “Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa,” Antimicrobial Agents and Chemotherapy, vol. 40, no. 3, pp. 677–683, 1996. View at Google Scholar
  14. P. H. Chandrasekar, L. R. Crane, and E. J. Bailey, “Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance emergence in serious infection by Pseudomonas aeruginosa in nonneutropenic patients,” Journal of Antimicrobial Chemotherapy, vol. 19, pp. 321–329, 1987. View at Google Scholar
  15. G. A. Pankey and D. S. Ashcraft, “In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 7, pp. 2959–2964, 2005. View at Publisher · View at Google Scholar · View at PubMed
  16. S. K. Pillai, R. C. Moellering Jr., and G. M. Eliopoulos, “Antimicrobial combinations,” in Antibiotics in Laboratory Medicine, V. Lorian, Ed., pp. 365–440, Lippincott Williams and Wilkins, Philadelphia, Pa, USA, 5th edition, 2005. View at Google Scholar
  17. F. C. Tenover, R. D. Arbeit, R. V. Goering et al., “Interpreting chromosomal DNA restriction patterns produced by pulsed- field gel electrophoresis: criteria for bacterial strain typing,” Journal of Clinical Microbiology, vol. 33, no. 9, pp. 2233–2239, 1995. View at Google Scholar
  18. CLSI, Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement, Clinical and Laboratory Standards Institute, Wayne, Pa, USA, 2009, CLSI document M100-S19.
  19. NCCLS, Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline, National Committee on Clinical Laboratory Standards, Wayne, Pa, USA, 1999, NCCLS document M26-A.
  20. V. Lorian, “In vitro simulation of in vivo conditions: physical state of the culture medium,” Journal of Clinical Microbiology, vol. 27, no. 11, pp. 2403–2406, 1989. View at Google Scholar
  21. R. H. K. Eng, A. Hsieh, and S. M. Smith, “Antibiotic killing of bacteria: comparison of bacteria on surfaces and in liquid, growing and nongrowing,” Chemotherapy, vol. 41, no. 2, pp. 113–120, 1995. View at Google Scholar
  22. V. Lorian and G. Satta, “Differences between in vitro and in vivo studies,” Antimicrobial Agents and Chemotherapy, vol. 32, no. 10, pp. 1600–1601, 1988. View at Google Scholar
  23. H. Smith, “Questions about the behaviour of bacterial pathogens in vivo,” Philosophical Transactions of the Royal Society B, vol. 355, no. 1397, pp. 551–564, 2000. View at Google Scholar